A Phase I Dose-Escalation Study of AG2037 [pelitrexol] Administered Once Weekly for Three Weeks to Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Pelitrexol (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 16 Sep 2005 New trial record.